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Radiotherapy for prophylaxis of heterotopic ossification (HO) is commonly used in high risk patients following
orthopedic surgery. While treatment is effective and can prevent morbidity associated with HO, with any dose of
radiation there is a concern of a radiation induced malignancy. Here we a report a case of radiation induced
osteosarcoma which developed 11 years after a single fraction of 700 cGy. We performed dosimetric analysis by
superimposing the patient’s original treatment field on a CT scan performed after the diagnosis. The radiotherapy
dose for this patient is lower than classically reported for radiation induced sarcomas. We identified greatest bony
destruction that was thought to be the epicenter of the tumor, and this was specially contoured on the diagnostic
CT scan. This volume appears to be located at the edge of the radiotherapy field. Fifty percent of the treated
volume received 240 cGy, the mean dose was 333 cGy. There was a variation across the treatment volume,
between 21.8 cGy and 717 cGy. While a rare complication, we stress the importance of informing regarding the risk
of a radiation induced malignancy following HO prophylaxis.Introduction
Heterotopic ossification (HO) of soft tissues following
traumatic fracture, orthopedic surgery, or central nervous
system injury, is a well known phenomenon described as
early as 1883 [1]. Although not entirely understood, the
pathogenesis is thought to involve stimulation of skeletal
growth factors, possibly prostaglandins and bone morpho-
genic proteins, which then orchestrate the improper devel-
opment of pluripotent mesenchymal cells towards ectopic
production of mature bone in the tissues surrounding joints
[2-5]. Usually HO presents as an incidental radiological
finding, or painless joint stiffening. More severe cases may
be painful, show signs of inflammation, or significantly im-
pact mobility [2,6]. The reported incidence is highly vari-
able. In high risk individuals following total hip arthroplasty
for example, the incidence of HO has been reported as high
as 90% [7].
The most common areas of HO development are around
the femoral neck and greater trochanter following hip
arthroplasty. Patients with a history of previous HO in
either hip, bilateral hypertrophic osteoarthritis, or post-
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reproduction in any medium, provided the orconsidered high risk patients. Men have a twofold higher
incidence than women [8].
The idea that RT could be used to prevent HO is
based largely on the assumption that osteoprogenitor
cells present in soft tissues in the beginning phases of
HO, would be highly mitotic and therefore sensitive to
RT. In 1981 Coventrey et al. concluded that RT was an
effective means of HO prevention [9,10].
The potential downsides to RT however, include effects
on fertility, and the possibility of radiation induced malig-
nancy. Although rare, radiation induced sarcoma (RIS)
has been associated with RT for various diseases at an in-
cidence of 0.09 and 0.11% [11]. The single 700 cGy frac-
tion typically used for HO prevention however, was until
recently, considered far lower than the doses commonly
believed necessary to induce sarcomatous development
[12-14]. To our knowledge, Mourad et al. is the only
group to report a case of RIS following HO prophylaxis
with two widely separated fractions to a total dose of
1400 cGy. Here we a second case of RIS which developed
11 years after only a single fraction of 700 cGy [14].
Case report
Initial presentation
A 26-year old Caucasian man sustained multiple injuries in
a motorcycle accident in 2001. He presented with a righttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as an open right distal tibia and fibular fracture which
necessitated a below-knee amputation (BKA). He was
treated with open reduction internal fixation (ORIF),
and within 72 hours, received post operative prophylactic
RT to the right hip including the acetabulum, femoral
head and neck, as well as the greater trochanter. Treat-
ment involved an open 8 × 15 field using anteroposterior-
posteroanterior (AP/PA) 6-MV photons to 7 Gy in one
fraction, without bone shielding.
The patient tolerated RT well. He did have multiple
revisions to the base of his right residual limb over the
years for episodes of poor wound healing and necrosis,
but otherwise had an uneventful course until three years
after RT, when he presented with a shooting painful
neuroma of the right BKA stump and femoral nerve
palsy. He did well following stump revision and neuroma
excision with intramedullary replacement of nerve end-
ings, and his femoral nerve palsy resolved.
Presentation of radiation induced sarcoma
Seven years later, now 37-years old, the patient began
to experience severe shooting pain along his right re-
sidual extremity. This had started just 10 hours after
switching to a new prosthesis, but the pain persisted
even on return to his old prosthesis, and radiographs
showed several benign appearing proximal tibial and
distal femoral bony cysts. He returned to the operating
room for a BKA stump revision and tibal/peroneal neur-
ectomy revision.
At the time of discharge, he began to notice a constant
right sided hip pain which rapidly worsened over the
next four months. The pain eventually became so in-
tolerable that he had to remain bed ridden for three
weeks, until he presented to the ED. A few days prior to
presentation, he had noticed a palpable mass in the right
hip. When positioned upright, he was most uncomfort-
able, and his pain localized primarily to the right hip and
medial thigh. The joint maintained its usual range of
motion, and he denied any fever, chills, nightsweats,
warmth or erythema. He had lost 30 pounds over the
preceding four months and described decreased appetite
and energy levels. His only pertinent lab findings were
mildly elevated CRP and ESR.
A plain film of the hip was read as unchanged from
previous x-rays, however, magnetic resonance imaging
(MRI) of the pelvis revealed a large soft tissue mass in
the right iliac wing measuring 15 × 14 × 15.4 cm with
intra-pelvic and extra-pelvic extension. Abdominal com-
puted tomography (CT) also exposed additional sclerotic
foci within the proximal right femur and sub-centimeter
low density lesions within the posterior right hepatic lobe.
Right external iliac and retroperitoneal lymph nodes were
not pathologically enlarged. A chest CT showed no lungmetastases, and a bone scan displayed only activity in the
right pelvic gluteal region.
Core biopsy of mass revealed high grade sarcoma with
cartilaginous differentiation suggestive of chondroblastic
osteosarcoma. The sample consisted of pleomorphic
spindle cells in a fibrous background containing eosino-
philic glassy osteoid like material. Immunohistochemisty
studies were positive for S-100, CD34, and negative for
CD99. Both Neuronspecific enolase (NSE) and CD57
showed patchy positivity within the cartilaginous and
spindle cell areas.
His disease was staged as T2 N0 M0 G3, stage IIB, and
the treatment plan included six cycles of cisplatin and
adriamycin. After completing the first two cycles his pain
noticeably improved. He continues to tolerate chemother-
apy reasonably well and the operational status of his mass
will be reassessed radiologically for possibly curative sur-
gery in the near future.
Discussion
Although HO is a benign disease, its propensity to ad-
versely affect quality of life, makes prophylactic treatment
appealing. Radiation therapy (RT) was first considered for
HO prophylaxis as early as the 1950’s when Cooley et al.
experimented with its effects on bone repair [15]. In 1971,
Craven et al. proposed that osteoprogenitor cells present
in the initial stages of HO development, were exquisitely
sensitive to RT due to a high mitotic rate [9]. Coventrey
et al. concluded RT was an effective means of HO preven-
tion. With a retrospective analysis of post operative total
hip arthroplasty patients, they showed that only 19%
of patients developed significant HO following RT
[10]. To maintain efficacy, treatment is generally given
within 4 days of surgical intervention based on studies by
Sylvester et al. After this window has elapsed efficacy of
RT drops precipitously [16]. The effectiveness of a single
fraction to 7 Gy has been determined equivalent to higher
doses or multiple fractions [17]. Healy et al. illustrated that
HO developed in only 10% of patients receiving 7 Gy
whereas 63% of patients receiving 5.5 Gy developed HO
[18]. A single fraction of 7 Gy has therefore become com-
mon practice.
Cahan et al. developed the criteria for defining RIS which
initially included; neoplastic growth within the RT field, no
pre-existing bone malignancy, histologic confirmation, and
a latency period of at least 5 years. Arlen et al. then modi-
fied these criteria to include; neoplasms in the peri-
irradiated areas, bone without a primary malignant osteo-
blastic lesion when the RT was given, and also included
tumors diagnosed earlier than 5 years from RT. Some
authors have suggested the latency period for RIS should be
considered as short as 1–6 months following RT [13,19,20].
The first and only other reported case of RIS asso-
ciated with HO prophylaxis, was discovered in a study
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matic fracture patients treated with RT to 7 Gy post ORIF,
providing an incidence rate of 0.058. That patient had
been irradiated 15 years earlier with a single 7 Gy fraction
at 37 years old, but he ultimately developed debilitating
HO in the treated hip, and was subsequently treated with
surgery as well as a second 7 Gy RT fraction. Sixteen
months later, he presented similarly to our patient, with
progressive thigh pain and soft tissue swelling. Although
treated aggressively, that patient died as a result of lung
metastasis shortly following diagnosis [14,21].
Brady et al. proposed that the presence of metastasis,
the extent of surgical resection, and the primary tumor
size before resection, could all be viewed as unfavorable
prognostic factors for RIS [22]. In general RIS originat-
ing at any site reportedly tends toward a worse outcome
than sporadic sarcomas [23]. The cumulative 5 year dis-
ease free survival is often reported in the range of 10-30%
and the median survival approaches one year [24]. A
recent article by Bjerkenhagen et al. suggested a poorer
prognosis of RIS is likely due to a higher incidence of
central tumor site, difficult or incomplete surgical resec-
tion based on location, microscopic tumor necrosis, and a
higher incidence of distant metastases [25]. Moreover,
some authors have suggested that fibrotic tissue changes
resulting from previous RT would prevent chemotherapy
from reaching target areas in RIS effectively [26]. The rela-
tive rarity of RIS, likely makes definitive conclusions on
comparative prognosis difficult. Often RIS presents insidi-
ously. In the case of HO prophylaxis, typical followup has
involved only periodic radiographs [14]. To the best of
our knowledge, there is no standard followup protocol
in place, but as illustrated in the above case, simple
radiographs may lack adequate sensitivity for detec-
tion of large masses. While early CT or MRI, wouldFigure 1 The original 8 × 15 field was digitally reconstructed and sup
osteosarcoma, and the treatment plan was subsequently recreated. T
epicenter of the tumor, and was specially contoured on the diagnostic CT
radiotherapy field, including both areas that received >700 cGy and <100 cundoubtedly improve sensitivity, they may not be feasible
for all patients, given the low incidence of RIS.
Pakos et al. suggested that the low incidence of RIS
following HO prophylaxis may be partly due to a primarily
older patient population receiving treatment. These
patients simply do not survive long enough to develop
RIS. In a study involving 1143 patients, the median age at
treatment was 61 [27]. Perhaps as younger patients are
followed longer, we may begin to see an increased inci-
dence of RIS.
RIS has been associated at an estimated incidence of
0.09 - 0.11% considering all cases of RT [11]. Mark et al.
reported an absolute risk of 0.03 - 0.8% where RT was
used to treat gynecologic malignancies [28]. Osteosar-
comas tend to be the most common type of RIS, followed
closely by fibrosarcoma [11,22,29].
It was previously believed that the development of RIS
likely required a minimum dose of at least 30–40 Gy,
and that doses of 55 Gy or more are associated with
increased risk of RIS [11,14,19]. A noteworthy point in
this report is that the dose for RIS in this patient is far
lower than what is classically reported in the literature.
Based on data from atomic bomb survivors, there is a
linear dose response relationship between radiation dose
and the incidence of carcinomas from 0.1 Sv to 2.5 Sv.
While low-dose exposure increases carcinoma risk, sar-
comas are typically observed in regions of tissue that
received higher doses of radiotherapy, either within or at
the edge of the radiotherapy field [30,31]. The patient
presented in this report received only one 7 Gy fraction to
to the surgical area, and his RIS subsequently developed
on the edge of the treatment field 11 years later.
The original 8 × 15 field was superimposed on a
current CT scan of the patient’s sarcoma Figure 1, and the
digitally reconstructed radiograph is shown in Figure 2.erimposed on a CT scan following the patient’s diagnosis of
he region of greatest bony destruction was thought to be the
scan. The volume appears to be located at the edge of the
Gy.
Figure 2 Digitally reconstructed radiograph (DRR) based on
original portal images. Portal images from patient’s original
treatment were recreated and superimposed on CT scan obtained
following the diagnosis of osteosarcoma. An open 8 × 15 field was
utilized for patient. Treatment was delivered using 6 MV photons,
with a source to skin distance (SSD) or 91.5 cm.
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treatment planning software. The region of greatest bony
destruction was thought to be the epicenter of the tumor,
and was specially contoured on the diagnostic CT scan.
This volume appears to be located at the edge of the radio-
therapy field, including areas that both received both
>700 cGy and < 100 cGy. Fifty percent of the treated
volume received 240 cGy, although there was a wideFigure 3 Dose-volume histogram of the contoured volume, including
volume received 240 cGy, although there was a wide variation across the t
21.8 cGy with a mean of 333 cGy.variation across the treatment volume, from a maximum
of 717 cGy to a minimum of 21.8 cGy with a mean of
333 cGy. The dose-volume-histogram (DVH) which was
developed based on the contoured volume is shown in
Figure 3.
Although RIS remains a rare treatment complication,
there are several other disadvantages of RT in this set-
ting including considerable costs, and scheduling diffi-
culties given the narrow 3–4 day treatment window. Post
operative pain and immobilization can also prove to be
significant boundaries to the precise positioning necessary
for treatment. Radiation’s impact on fertility has also been
a concern in younger patients, however Patel et al. showed
that the majority of testicular dose can be shielded against
effectively [32].
Non-steroidal anti-inflammatory drugs (NSAIDs) can
serve as an alternative method of HO prophylaxis pre-
sumably through systemic inhibition of prostaglandins
that promote osteoprogenitor development. A typical
and effective regimen is Indomethacin 25–50 mg three
times a day, for 6 weeks, although other NSAIDs and
different dosage schedules may be used. Compared to
RT, NSAIDs are a considerably less expensive option,
but patients often have poor compliance due to gastritis
or other GI complications. There is also a more signifi-
cant incidence of nonunion with NSAIDs, a problem
that can be avoided by shielding prostheses in RT [2].
Post surgical use of NSAIDs also produces considerable
bleeding risks given these patients are usually anti-
coagulated with heparin or warfarin for deep venous
thrombosis prophylaxis [27]. Pakos et al. also comparedthe areas of greatest bony destruction. Fifty percent of the treated
reatment volume, from a maximum of 717 cGy to a minimum of
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and found RT to be slightly superior at preventing the
most severe cases of HO development, however the
absolute difference was very small at only 1.2% [27].
Conclusions
Radiotherapy remains an effective method of prophylaxis
for HO in high risk patients. We have presented the
above case to increase awareness in literature of this rare
complication following HO prophylaxis. Younger patients
have an increased risk of developing a secondary malig-
nancy with radiotherapy, and it is possible that we may
see an increased frequency of RIS in the future. The dif-
ficulty of early detection and a generally poor progno-
sis of RIS suggest that imaging follow-up protocols
may be reasonable in younger patients. Furthermore,
it is important to inform patients regarding the risk
of a radiation induced malignancy. As many of these
patients are on narcotic pain medications post-operatively,
when possible, radiation oncology consultation should be
obtained prior to surgery so that patients can be best
informed of the risks and benefits of treatment. Based on
the reported case, we suggest that prior to recommending
prophylactic RT for young patients at risk for HO, the
potential risks should be weighed strongly against the
benefits.
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